First‐in‐human development of a pharmacodynamic biomarker for PAC(1) receptor antagonists using intradermal injections of maxadilan

Maxadilan, a potent vasodilator peptide, selectively activates the PAC(1) receptor, a promising target for migraine therapy. Therefore, maxadilan has been suggested as a tool to study the pharmacodynamics (PDs) of PAC(1) receptor antagonists. The objectives of this first‐in‐human study were to: (1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Marynissen, Heleen, Buntinx, Linde, Bamps, Dorien, Depre, Marleen, Ampe, Els, Van Hecken, Anne, Gabriel, Kristin, Sands, Steve, Vargas, Gabriel, de Hoon, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372410/
https://www.ncbi.nlm.nih.gov/pubmed/35621246
http://dx.doi.org/10.1111/cts.13309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372410/
https://www.ncbi.nlm.nih.gov/pubmed/35621246
http://dx.doi.org/10.1111/cts.13309

Ejemplares similares